Head-to-head · Cost-Efficiency Index
Claya vs Harbor
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Claya
Cost-first shoppers who want a same-price-any-dose semaglutide plan, for shoppers willing to consider a multi-month prepay to get the advertised rate.
Visit ClayaHarbor
Cost-first shoppers who want price-sensitive shoppers who want a 'locked, no-increase' pricing promise on entry-tier compounded GLP-1s.
Visit HarborThe verdict
Claya and Harbor tie on the Cost-Efficiency Index at 69/100, so neither wins outright on the numbers. For most shoppers we'd start with Claya (ranked #97, a hair above #100) — Cost-first shoppers who want a same-price-any-dose semaglutide plan, for shoppers willing to consider a multi-month prepay to get the advertised rate. But Harbor is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Claya.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Claya | Harbor |
|---|---|---|
| Cost-Efficiency Index | 69/100 | 69/100 |
| Semaglutide / mo | $149/mo (all doses, compounded) | $99/mo (starting dose, compounded) |
| Tirzepatide / mo | $199/mo (starting dose, compounded) | $149/mo (starting dose, compounded) |
| Semaglutide / yr (modeled) | $1,788 | $1,188 |
| Tirzepatide / yr (modeled) | $2,388 | $1,788 |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | Yes | No |
| Brand-name access | Compounded only | Yes |
| Rank here | #97 | #100 |
Claya
69/100Where the value is
- Semaglutide is explicitly 'same price regardless of dosage' at $149/mo, removing dose-tier guesswork
- LegitScript Certified, BBB Accredited, and HIPAA Compliant badges all displayed together
- '$100 off your first month' promo code (100CLAYA) published openly with no intake required to see it
The tradeoffs
- The advertised $149/$199 rates are qualified elsewhere on the same page as available 'with select multi-month plans' — a shopper reading only the 'a month' headline could reasonably assume pure month-to-month billing when a prepay term may be required
- No state coverage list is published anywhere on the public site
Harbor
69/100Where the value is
- Among the lowest entry-tier prices seen in this set ($99 semaglutide / $149 tirzepatide)
- Explicit 'No Price Increases / Locked pricing' claim, addressing a common bait-and-switch risk
- LegitScript badge verifiably tied to the visitharbor.com domain itself
The tradeoffs
- 'As low as' framing without a visible full pricing/tier page (404'd)
- No individual is designated 'medical director' despite three physicians being pictured
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.